Auner H, Petru E, Hofmann H M, Pickel H, Pürstner P
Department of Obstetrics and Gynecology, University of Graz, Austria.
Arch Gynecol Obstet. 1989;246(4):227-31. doi: 10.1007/BF00934523.
In vitro chemosensitivity to cisplatinum, adriamycin, cyclophosphamide, and 5-fluorouracil was investigated in 58 cases of ovarian carcinoma using Volm's short-term test. These in vitro results were retrospectively correlated with the relapse-free interval. Operative treatment in all patients (FIGO stage I (5), III (43), IV (10)) comprised maximum debulking procedure including hysterectomy, adnexectomy, omentectomy, pelvic and in most cases additionally paraaortic lymphadenectomy. Subsequently, all patients were treated with the cisplatinum-epirubicin-cyclophosphamide regimen. 33/58 tumors (66%) were sensitive in vitro (inhibition of nucleic acid precursor incorporation of more than 45% as compared to untreated controls). The median relapse-free interval of patients with sensitive tumors was significantly longer than that of those with resistant carcinomas (30.3 versus 22.6 months, respectively; P less than 0.05). Histopathological evaluation showed the majority of serous cystadenocarcinomas to be sensitive (26/33 = 79%, P less than 0.05).
采用Volm短期试验对58例卵巢癌患者进行了顺铂、阿霉素、环磷酰胺和5-氟尿嘧啶的体外化学敏感性研究。这些体外研究结果与无复发生存期进行了回顾性关联。所有患者（国际妇产科联盟（FIGO）分期：I期（5例）、III期（43例）、IV期（10例））均接受了最大程度减瘤手术，包括子宫切除术、附件切除术、大网膜切除术、盆腔淋巴结清扫术，多数情况下还包括主动脉旁淋巴结清扫术。随后，所有患者均接受顺铂-表柔比星-环磷酰胺方案治疗。58例肿瘤中有33例（66%）在体外敏感（与未治疗的对照组相比，核酸前体掺入抑制率超过45%）。敏感肿瘤患者的无复发生存期中位数显著长于耐药癌患者（分别为30.3个月和22.6个月；P<0.05）。组织病理学评估显示，大多数浆液性囊腺癌敏感（26/33 = 79%，P<0.05）。
